Medical College of Wisconsin
Medical College of Wisconsin Cancer Center

Cell Therapy (CTSR)

The Cell Therapy Shared Resource provides state-of-the-art processing and production of cell therapy products for clinical use, expertise in the translation of cellular therapies to the clinic, and cutting-edge instrumentation supporting the development of novel immunotherapy strategies and insights on mechanisms of action for effective therapies.

Scheduling, Location, and Hours of Operation

Pavilion Building | Monday–Friday, 7 a.m.-6 p.m.
Extended hours are available for time-sensitive patient care needs. Questions? Contact celltherapyresearch@mcw.edu.
Submit a Cell Therapy iLab request

Services and Technologies

The CTSR provides initial project, clinical trial, and grant consultation services, free of charge, to help users understand the technical aspects, advantages, limitations, turnaround time, and cost of services.
all
Standard-of-care Clinical Processing
  • HSC processing including CD34+ selection
Cell Processing and Product Manufacturing
  • CAR T-cell manufacturing under FDA-approved IND (e.g., Miltenyi Biotec ClinicMACS Prodigy Platform)
  • ɑ/β T cell-depletion of HSC products for clinical trials
Immune Profiling

Leadership

headshot

Peiman Hematti, MD

Director, Cell Therapy Shared Resource (CTSR)

View Profile

headshot

Tyce Kearl, MD, PhD

Co-Director, Cell Therapy Laboratory Shared Resource

tkearl@mcw.edu

View Profile

Notable Publications

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. (Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators) N Engl J Med 2023 Jun 22;388(25):2338-2348 PMID 37342922 PMCID: PMC10575613 6/21/2023 SCOPUS ID: 2-s2.0-85164529275 6/21/2023

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. (Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN) Haematologica 2023 Feb 01;108(2):588-593 PMID: 36200427 PMCID: PMC9890001 SCOPUS ID: 2-s2.0-85147234722 10/07/2022

Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. (Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN) Am J Hematol 2022 Dec;97(12):1580-1588 PMID: 36068950 DOI: 10.1002/ajh.26718 Scopus ID: 2-s2.0-85138335080 9/08/2022

KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial. (Pulsipher MA, Ahn KW, Bunin NJ, Lalefar N, Anderson E, Flower A, Cairo MS, Talano JA, Chaudhury S, Kitko CL, Duke JL, Monos D, Leung W, Dvorak CC, Abdel-Azim H) Blood 2022 Dec 15;140(24):2556-2572 PMID: 35776909 PMCID: PMC9918850 SCOPUS ID: 2-s2.0-85144585749 7/02/2022

Black patients with multiple myeloma have better survival than white patients when treated equally. (Dong J, Garacci Z, Buradagunta CS, D'Souza A, Mohan M, Cunningham A, Janz S, Dhakal B, Thrift AP, Hari P) Blood Cancer J. 2022 Feb 24;12(2):34 PMID: 35210395 PMCID: PMC8873507 SCOPUS ID: 2-s2.0-85125303734 2/26/2022

National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. (Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J) J Clin Oncol 2021 Jun 20;39(18):1971-1982 PMID 33905264 PMCID: PMC8260905 SCOPUS ID: 2-s2.0-85108386444 4/28/2021

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. (Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P) Nat Med 2020 Oct;26(10):1569-1575 PMID: 33020647 DOI: 10.1038/s41591-020-1081-3 SCOPUS ID: 2-s2.0-85092105030 10/07/2020